The EU Pharmaceutical Package: What the Council's Adoption Means for Canadian Sponsors

After more than two years of negotiation, the European Union's largest overhaul of its medicines law in two decades has cleared a major hurdle. On 28 September 2026 the Council of the European Union adopted its position on the pharmaceutical package, the pair of laws that will replace rules first written in 2001 and 2004. The package is not yet in force. The European Parliament still has to take its final plenary vote, expected in the autumn of 2026, before the texts are published and the clock starts. What the Council's adoption does is lock in the shape of the reform, and that shape matters to any company that sells medicines in Europe or plans to.

For Canadian sponsors, the reform is not a distant European story. It changes how long a new medicine is protected from competition, what a company must do to earn the longest protection, and what obligations attach to keeping a product on the European market. This article explains what the package is, what it changes, and the practical steps Canadian pharmaceutical and biotech companies should take now, while the rules are still settling.

Executive Summary

The EU pharmaceutical package is a reform of the Union's general medicines law, made up of a new Regulation and a new Directive. The Council adopted its position on 28 September 2026, and the European Parliament's final vote is the last step before the texts become law. The reform lowers the guaranteed baseline of regulatory protection, then lets companies earn it back by meeting public health conditions, adds new security of supply and shortage duties, and introduces an environmental risk assessment requirement. Most provisions will apply about two years after the texts enter into force, which gives sponsors time to plan but not time to ignore it.

What the EU Pharmaceutical Package Is

What it is: the pharmaceutical package is a reform of the European Union's general pharmaceutical legislation, proposed by the European Commission in April 2023. It replaces the framework built on Directive 2001/83/EC and Regulation 726/2004, and folds in the separate rules for orphan and paediatric medicines. The reform is delivered through two new instruments, a Regulation and a Directive, that work together. Why it matters: these are the rules that govern how medicines are authorised, protected from competition, supplied and withdrawn across all EU and EEA markets.

The stated goals of the reform of the EU pharmaceutical legislation are to improve timely and equitable access to medicines across member states, simplify and speed up authorisation, strengthen measures against shortages, and support innovation while keeping the system affordable. The Council and Parliament reached a provisional political agreement in December 2025, as set out in the Council's announcement of the deal, and the 28 September 2026 adoption turned that agreement into the Council's formal position. The sequence is set out in the table below.

What Changes: Protection Periods and Incentives

What changes: the headline change is the structure of regulatory protection for new medicines. Today the EU gives a guaranteed baseline of about ten years. Under the reform the guaranteed baseline falls to nine years, built from eight years of regulatory data protection plus one year of market protection, and companies earn additional protection by meeting public health conditions. Why it matters: the longest protection is no longer automatic. It is tied to behaviour the EU wants to encourage, such as launching across member states and addressing unmet medical need.

Under the agreed texts, a company can add up to two further years of protection by meeting conditions, which can bring the total to eleven years. A separate transferable exclusivity voucher can add one more year of regulatory data protection. The voucher is aimed at priority antimicrobials to help fight antimicrobial resistance, it can be transferred once, it cannot be used on products with annual Union gross sales above 490 million euros, and the scheme is capped at a limited number of vouchers over its lifetime. The comparison below sets the current rules against the reform as agreed.

For innovators, the practical message is that the richest protection now has to be earned through launch and access commitments, not assumed. For generic and biosimilar developers, a shorter guaranteed baseline can mean earlier entry for some products, though the exact timing depends on how each originator earns its extensions. If your pipeline includes biosimilars, the European calculus connects to the Canadian one we set out in our analysis of biosimilars in Canada and what sponsors must still prove.

Security of Supply and Shortage Obligations

Why it matters: the reform strengthens the duties that come with keeping a medicine on the European market. Marketing authorisation holders face clearer obligations to ensure appropriate and continued supply, to give earlier notice of withdrawals and shortages, and to prepare shortage prevention plans for certain products. These build on the direction already set by recent EU shortage rules, which we covered in our explainer on EMA shortage prevention plans under Article 117. What to do: a Canadian sponsor that holds or plans to hold an EU authorisation should treat supply continuity as a regulatory obligation, not only a commercial choice, and build the monitoring, notification and contingency processes to match.

The reform also gives authorities more tools to act on critical shortages and to coordinate across member states. For a company whose European supply depends on a Canadian or third country manufacturing site, this raises the importance of a resilient supply chain, qualified alternative sources where feasible, and documentation that can demonstrate, on request, how continuity of supply is being managed.

Environmental Risk Assessment and Faster Assessment

What changes: the reform strengthens the environmental risk assessment that accompanies a marketing authorisation application, including the risk from manufacturing and from antimicrobial resistance, and allows an application to be refused or conditioned where the assessment is inadequate. It also aims to shorten EMA assessment timelines and to simplify procedures, including a move toward electronic product information. How it affects compliance: an environmental risk assessment is no longer a formality to be completed late in a dossier. It is part of the data package, and gaps in it can delay or block an authorisation.

These changes do not sit in isolation. They arrive alongside a broad rewrite of the EU Good Manufacturing Practice guide through 2026 to 2028, which we track in our EU GMP guide revision roadmap. A Canadian sponsor planning European submissions over the next few years should expect both the legislative framework and the technical guidance beneath it to be moving at the same time.

Why It Matters for Canadian Sponsors

What to do: Canadian pharmaceutical and biotech companies with European ambitions should treat the Council's adoption as the signal to plan, not wait. The protection math has changed, the conditions to earn the longest protection are new, and the supply and environmental obligations add work that is better scoped early. Companies that run parallel strategies in Canada and the EU should also watch how the two systems are converging on lifecycle oversight, a theme we explored in our piece on Health Canada's terms and conditions and agile licensing. The reform rewards companies that can plan an EU wide launch and demonstrate that they meet unmet needs, which is as much a commercial and clinical strategy question as a regulatory one.

There is time, but not unlimited time. Most of the new rules apply about twenty four months after the texts enter into force, and transitional provisions will let products already in the pipeline rely on the previous protection periods in defined circumstances. That transition window is exactly when submission timing, lifecycle planning and change management decisions pay off, and it connects to the lifecycle tools we discuss in our overview of lifecycle management under ICH Q12. The sponsors who understand the new rules while competitors are still reading headlines will make better timing decisions.

EU Pharmaceutical Reform Readiness Checklist

Use this checklist to prepare for the reform while it finishes its passage through the European institutions.

• Map each European product and pipeline asset against the new 9 year baseline and the conditions needed to reach 11 years.
• Assess whether an EU wide launch and access strategy is realistic for your asset, since the richest protection now depends on it.
• Review whether any asset could qualify for the antimicrobial voucher, and model the sales and transfer limits before relying on it.
• Build or upgrade security of supply, shortage notification and shortage prevention processes for products you hold or plan to hold in the EU.
• Strengthen the environmental risk assessment in your dossiers, including manufacturing and antimicrobial resistance considerations.
• Model submission timing against the roughly 24 month transition and the transitional rules for products already in the pipeline.
• Track the European Parliament plenary vote and the final published texts, since details can shift until the law is adopted.
• Align your EU plans with your Health Canada strategy so that a single development programme can support both markets efficiently.

Common Mistakes to Avoid

The first mistake is treating the Council's adoption as the end of the process. It is not. The European Parliament still has to vote, and while the core deal is settled, details can change until the texts are published. The second is assuming the old ten year baseline still applies to future products. The reform lowers the guaranteed baseline and makes the top end conditional, so a protection assumption built on the current rules can overstate the exclusivity a new product will actually receive. The third is leaving the environmental risk assessment and the supply obligations to the end of a programme, when both now carry the power to delay an authorisation or trigger enforcement. The fourth, specific to Canadian sponsors, is planning the EU and Canadian submissions in separate silos, which wastes data and misses chances to align one development programme to serve both markets.

Frequently Asked Questions

Is the EU pharmaceutical package now law?

Not yet. The Council of the EU adopted its position on 28 September 2026, which is a major step, but the European Parliament must still take its final plenary vote, expected in the autumn of 2026. Once both institutions adopt the texts, they are published in the Official Journal and enter into force 20 days later. Most provisions then apply after a transition of about 24 months.

How does the reform change data and market protection?

The guaranteed baseline falls from about ten years today to nine years, made up of eight years of regulatory data protection and one year of market protection. Companies can earn up to two more years by meeting conditions such as addressing an unmet medical need, which can bring the total to about eleven years. A transferable voucher for priority antimicrobials can add one further year of data protection, subject to limits.

What is the antimicrobial voucher?

It is a transferable exclusivity voucher designed to reward the development of priority antimicrobials, in response to antimicrobial resistance. The voucher grants one extra year of regulatory data protection, can be transferred once to another product, cannot be applied to products with annual Union gross sales above 490 million euros, and the scheme is capped at a limited number of vouchers over its lifetime. It is one of the more debated parts of the reform.

Does the reform affect generic and biosimilar entry?

It can. A lower guaranteed baseline may bring forward the earliest possible entry for some products, but the actual date depends on how the originator earns its conditional extensions and any voucher. Generic and biosimilar developers should model entry timing product by product rather than assuming a single rule, and watch the final texts closely.

What new supply obligations does the reform add?

Marketing authorisation holders face clearer duties to ensure continued and appropriate supply, to notify shortages and withdrawals earlier, and to prepare shortage prevention plans for certain products. Authorities also gain stronger tools to coordinate on critical shortages. A Canadian sponsor holding an EU authorisation should build the monitoring, notification and contingency processes to meet these duties.

What should a Canadian sponsor do first?

Start by mapping your European portfolio and pipeline against the new protection math, so you understand what exclusivity each asset will realistically receive. Then assess whether an EU wide launch and unmet need position is achievable, scope the supply and environmental obligations, and model your submission timing against the transition. A focused gap assessment turns a complex reform into a concrete plan.

How MFLRC Can Help

MF License and Regulatory Consultants helps Canadian sponsors turn European regulatory change into a plan. Our pharmaceutical regulatory support covers EU and Canadian market entry strategy, protection and lifecycle analysis, and dossier readiness, including the environmental risk assessment and supply obligations the reform strengthens. Our regulatory affairs, licensing and import or export services help you align one development programme across Canada, the EU and other markets, and our gap assessments and quality system work prepare you for the submissions and inspections that follow. We translate reform into timing, documentation and decisions.

Planning to launch or maintain a medicine in Europe as the pharmaceutical package takes shape? Book a regulatory strategy consultation with MFLRC and map your portfolio against the new rules before they take effect.

Conclusion

The EU pharmaceutical package is the biggest change to European medicines law in twenty years, and the Council's adoption on 28 September 2026 means its shape is now clear even though it is not yet law. For Canadian sponsors, the reform changes the value of a European authorisation, the behaviour needed to protect it, and the obligations that come with keeping a medicine on the market. The transition gives companies time to prepare, and that time is the advantage. The sponsors who map their portfolios against the new rules now will make sharper decisions about where, when and how to bring their medicines to Europe.

Sources and References

• European Commission, Reform of the EU pharmaceutical legislation
• Council of the EU, Pharma package: Council and Parliament reach a deal, 11 December 2025
• Regulatory Affairs Professionals Society, Council of the EU adopts pharma package, September 2026
• European Medicines Agency, official website